Population Pharmacokinetic Analysis of Dalbavancin, a Novel Lipoglycopeptide

@article{Buckwalter2005PopulationPA,
  title={Population Pharmacokinetic Analysis of Dalbavancin, a Novel Lipoglycopeptide},
  author={Mary Buckwalter and James A. Dowell},
  journal={The Journal of Clinical Pharmacology},
  year={2005},
  volume={45}
}
Dalbavancin is a lipoglycopeptide antibiotic in clinical development as a once‐weekly treatment for serious infections. A total of 532 patients, consisting of 502 patients with skin and soft tissue infections requiring parenteral therapy and 30 patients with catheter‐related bloodstream infections, was available for population pharmacokinetic analysis. The majority of patients (78.4%) received dalbavancin intravenously as a 1000‐mg dose on day 1 and a single 500‐mg dose on day 8. A 2… 
Clinical Pharmacokinetics and Pharmacodynamics of Dalbavancin
TLDR
Recent data suggest usefulness in the treatment of infections beyond ABSSSI, with convenient dosing and redosing strategies for complicated infections requiring extended treatment durations suggested.
Review of the pharmacokinetics of dalbavancin, a recently approved lipoglycopeptide antibiotic
TLDR
It is concluded that dalbavancin, despite high protein binding offers pharmacokinetic benefits such as good tissue penetration and long half-life, may be a drug of choice and replace more resource demanding intravenous drugs to treat serious infections in a hospital setting.
In Vivo Pharmacodynamic Activity of the Glycopeptide Dalbavancin
TLDR
The dose-dependent efficacy and prolonged elimination half-life of dalbavancin support the widely spaced regimens used in clinical trials and the free-drug 24-h AUC/MIC targets identified in these studies should be helpful for discerning rational susceptibility breakpoints.
Pharmacokinetic‐Pharmacodynamic Modeling of Dalbavancin, a Novel Glycopeptide Antibiotic
TLDR
The analysis supports the use of once‐weekly dosing regimens of dalbavancin in the treatment of complicated skin and skin structure infections.
Dalbavancin Population Pharmacokinetic Modeling and Target Attainment Analysis
TLDR
This analysis represents the update of the population pharmacokinetics modeling and target attainment simulations performed with data from the single‐dose safety and efficacy study and an unrelated but substantial revision of the preclinical pharmacokinetic/pharmacodynamic target (fAUC/MIC).
Population Pharmacokinetics of Dalbavancin and Dosing Consideration for Optimal Treatment of Adult Patients with Staphylococcal Osteoarticular Infections
TLDR
Giving a regimen of two 1,500-mg doses of dalbavancin 1 week apart may ensure efficacy against both MSSA and MRSA up to 5 weeks in patients with OA infections.
Dalbavancin: a new lipoglycopeptide antibiotic.
  • J. Bailey, K. Summers
  • Medicine
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • 2008
TLDR
Dalbavancin has enhanced activity against gram-positive bacteria and unique pharmacokinetics compared with existing drugs in its class and appears to be safe and efficacious for use against common infections, including complicated skin infections and catheter-related bloodstream infections.
Dalbavancin Pharmacokinetics and Safety in Children 3 Months to 11 Years of Age
TLDR
Dalbavancin pediatric dosing that matched adult exposure was identified and was well tolerated in the study population, and was assessed as possibly or probably related to treatment.
Intravenous and Intraperitoneal Pharmacokinetics of Dalbavancin in Peritoneal Dialysis Patients
TLDR
Dalbavancin at 1,500 mg administered intravenously can be utilized without dose adjustment in peritoneal dialysis patients and will likely achieve the necessary peritoneAL fluid concentrations to treat peritonitis caused by typical Gram-positive pathogens.
Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic.
TLDR
Dalbavancin, a new lipoglycopeptide, has the desirable characteristics of increased in vitro activity, compared with vancomycin, for most gram-positive pathogenic bacteria, as well as an extremely long half-life, permitting once-weekly intravenous dosing.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 21 REFERENCES
Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide.
TLDR
The efficacy study showed that a two-dose weekly dalbavancin dosage regimen was well tolerated and associated with a higher clinical response rate than the comparator regimens.
Tolerability, Pharmacokinetics, and Serum Bactericidal Activity of Intravenous Dalbavancin in Healthy Volunteers
TLDR
The long half-life and maintenance of SBA against MRSA for 1 week suggest that weekly dosing may be feasible and the long tolerated dose, characterize the pharmacokinetics, and obtain serum bactericidal activity (SBA) data for intravenous dalbavancin are suggested.
Pharmacokinetics and excretion of dalbavancin in the rat.
TLDR
Dalbavancin is not selectively retained in any single organ, tissue or blood component and is completely eliminated by both renal and non-renal routes in rats, useful in designing and interpreting animal infection model studies used to select the dose for human studies.
Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections.
TLDR
It is suggested that a regimen of 2 doses of dalbavancin administered 1 week apart is effective in the treatment of complicated, gram-positive bacterial SSTIs and warrants further study.
Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates.
TLDR
Dalbavancin activity indicates that the new glycopeptide has significant activity, superior to available agents in the class, and a potency that was uniform across geographically sampled organisms.
In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic.
TLDR
The data from these studies show that BI 397 combines an excellent in-vitro antibacterial activity with favourable pharmacokinetic behaviour resulting in potent in- vivo activity.
Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM.
TLDR
Xpose is presented, a model building aid for population PK/PD analysis using NONMEM, which simplifies the task of producing documentation, data set checkout plots, goodness of fit plots and graphical model comparison.
The safety and pharmacokinetics of dalbavancin in subjects with renal impairment or end-stage renal disease
  • Clin Microbiol Infect
  • 2005
Drugs metabolized by known P450’s [reference list
  • Indiana School of Medicine. Available at: http://medicine.iupui .edu/flockhart/clinlist.htm. Accessed March
  • 2004
Comparative activity of dalbavancin tested against 7,771 isolates from the
  • Antimicrobial Agents and Chemotherapy
  • 2003
...
1
2
3
...